Monopar Therapeutics Inc. (MNPR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 4.02M USD | Liabilities, Current |
| Cash and equivalents | 52.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 52.61M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.02M | $52.76M | $52.61M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $2.46M | $52.54M | $52.37M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $2.74M | $61.83M | $60.88M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $2.57M | $127.68M | $127.50M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $1.58M | $39.50M | $39.33M | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $39.71M | $39.51M | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $45.82M | $45.53M | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $6.02M | $5.80M | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $6.12M | $6.88M | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $7.81M | $8.22M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.76M | $7.27M | $6.54M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.98M | $5.52M | $7.65M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.50M | $7.21M | $9.11M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.89M | $5.73M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.13M | $8.19M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.91M | $14.32M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.19M | $16.46M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.07M | $17.82M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $20.30M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $22.34M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $24.29M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $806.27K | $25.72M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $1.18M | $16.74M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $609.84K | $17.98M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $573.13K | $12.55M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $443.52K | $12.59M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $724.16K | $13.21M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $483.67K | $4.49M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $468.27K | $5.13M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $579.99K | $5.88M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $399.55K | $6.89M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $311.89K | $7.62M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $323.06K | $7.42M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $290.60K | $8.17M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $311.87K | $8.98M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $64.51K | $2.07M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |